###### Key questions

What is already known about this subject?
=========================================

-   According to current guidelines, a multidisciplinary heart valve team is recommended for the evaluation of treatment in patients with severe valvular heart disease; however, there is a lack of data supporting this approach, and the decision-making process is not well defined.

What does this study add?
=========================

-   In this single-centre cohort study including 400 patients, we thought to analyse the patient selection process by the heart team for different treatment options in patients with mitral valve regurgitation and the outcome after treatment.

-   The multidisciplinary heart team assigned only low-risk patients with favourable anatomy to surgical repair, while high-risk patients underwent Mitraclip or surgical replacement.

-   This strategy was associated with lower than expected in-hospital mortality for Mitraclip patients and high 4-year survival rates for patients undergoing surgical or percutaneous repair of isolated primary mitral regurgitation.

How might this impact on clinical practice?
===========================================

-   A consequent selection process by the heart team requires reduction of factors often biassing treatment assignment.

-   In view of future treatment options including percutaneous mitral valve replacement, the heart team selection process becomes even more important and may influence patient outcome.

Introduction {#s1}
============

Patients undergoing surgical treatment for mitral regurgitation (MR) have been studied for decades. In selected patient populations (relatively young patients, primary MR), surgical mitral valve repair (MVrepair) leads to outstanding repair rates and excellent long-term survival.[@R1] However, in patients with secondary MR, and in particular in ischaemic heart disease, it is an ongoing debate whether surgical MVrepair or mitral valve replacement (MVR) is the treatment of choice.[@R3] In addition, for elderly patients outcomes after mitral valve (MV) surgery are far less favourable.[@R4] Percutaneous MV repair using the Mitraclip (MC) procedure has proven to be a treatment alternative for surgical high-risk patients with MR.[@R5] However, these specific cohorts or randomised trials exclude many patients seen in daily practice, and single surgeon experiences in few, highly specialised centres may not represent reality in large parts of the world where patients are evaluated and treated by heart teams.

The concept of an multidisciplinary heart team (MDT) has evolved to a central role in modern cardiovascular care to ensure the most appropriate individual treatment and to improve the outcome for each patient.[@R7] However, evidence supporting such an approach is lacking, in particular for MV regurgitation.[@R8] Furthermore, the exact patient selection process performed by the MDT has not been described. The aim of this study was to report the selection process and the outcomes of patients undergoing MV treatment in a centre with an institutionalised MDT approach.

Methods {#s2}
=======

Patient population {#s2-1}
------------------

In this retrospective cohort analysis, all patients treated for MR at the Heart Clinic Zurich between July 2013 and September 2018 were included. Three patients treated with percutaneous valve-in-valve/ring replacement were excluded as they have been reported elsewhere.[@R9] Surgical treatment included isolated or combined MV surgery (MV surgery plus coronary bypass and/or additional valve surgery). In the percutaneous group, interventions counted as combined instead of isolated if the MC procedure was part of a beforehand planned series of interventions, including percutaneous coronary and/or other valve interventions. Clinical data, including follow-up data, were extracted from patient charts and by telephone interview. Twelve patients were lost to follow-up. Echocardiographic parameters were quantified according to current guidelines.[@R10]

MDT decision {#s2-2}
------------

The MDT of the Heart Clinic Zurich consists of cardiac surgeons (two dedicated MV surgeons with \>600 MVrepair operations each), interventional cardiologists (three experienced in MC procedure, main operator with \>500 MC interventions), imaging and heart failure specialists as well as cardiac anaesthetists. The MDT meets weekly to discuss all heart valve cases and works as an organisationally and financially independent unit. In cases of disagreement between the team members regarding optimal treatment, decision is taken according to the majority principle of present team members.

According to current guidelines, the MDT assigned all patients to one of the three treatment strategies (MC, surgical MVrepair or primary MV replacement (I° MVR)).[@R8] The primary MDT's treatment intention was surgical MVrepair. Anatomical amenability for MVrepair was analysed using three-dimensional transoesophageal echocardiography.[@R13] For patients deemed high risk for surgery but with suitable MV anatomy, percutaneous MV repair using MC was performed.[@R14] Patients were considered 'high surgical risk' based on a combination of factors, including estimated mortality (EuroScore II) \>4%, age \>80 years and additional clinical risk factors not covered by EuroScore II such as frailty, obesity or liver disease. If neither MVrepair nor MC seemed feasible according to anatomical criteria, or the surgical repair effort appeared unreasonably high, primary MV replacement was performed.

In-hospital outcome {#s2-3}
-------------------

In-hospital outcome was measured as success of the initial treatment strategy and in terms of mortality. 'Treatment success' in surgical patients was defined as survival with residual MR ≤mild, no secondary MVR and absence of MV stenosis at discharge. The term 'secondary' MVR was used for patients in whom primary MVrepair failed and the surgical team decided intraoperatively to convert to MVR. Absence of mitral stenosis was defined as mean transvalvular gradient \<5 mm Hg, or a gradient ≥5 mm Hg when haemodynamically explained by heart rate and/or haemoglobin level. In MC patients, a residual MR ≤moderate at discharge with a reduction in MR by ≥1 grade from baseline was still considered as success. Pure technical success for MC patients was defined according to the M-VARC criteria.[@R5]

Follow-up outcome {#s2-4}
-----------------

Primary end points during follow-up were all-cause mortality and a combined endpoint, consisting of all-cause mortality, cardiovascular rehospitalisation and MV reintervention.

Secondary end points during follow-up were severity of MR and dyspnoea according to the New York Heart Association classification (NYHA) after 3 months, 1 year and at the last follow-up examination before January 2019. Secondary end points were analysed separately for the accomplished intervention at discharge (MC, MVrepair or all MVR).

Statistical analysis {#s2-5}
--------------------

Continuous data are expressed as mean±SD, and categorical data as number and percentage (%). To compare data, we used the t-test, one-way analysis of variance (ANOVA) or repeated measures ANOVA, as appropriate. The Kaplan-Meier survival curves were constructed to estimate event-free survival for different subgroups and were compared with the log rank (Mantel-Cox) test. Univariate and multivariate Cox-regression model was used to analyse the predictors on combined end points. The conditional average treatment effect was estimated for various subgroups of patients as the difference in probability of a combined end point within 1 year between MVrepair and MC using an augmented inverse probability weighted estimate. Both the treatment and outcome model were fitted with a Random Forest regression and a missForest imputation was used for 5.9% missing covariate values, while the width of the CIs was approximated using Bootstrap. The level of significance was set at a p value of \<0.05. All statistical analyses were performed using SPSS software (V.25.0, SPSS, Chicago, Illinois, USA) and R (V.3.4.1).

Results {#s3}
=======

MDT decision and baseline characteristics {#s3-1}
-----------------------------------------

[Figure 1](#F1){ref-type="fig"} demonstrates the assignment to the initial treatment strategy. Seventy-five per cent of MVrepair and 55% of MVR patients had isolated MV surgery. Baseline characteristics are summarised in [table 1](#T1){ref-type="table"}. Within the MC population, 57.0% of patients were treated for primary (EuroScore II 5.2%) and 35.7% for secondary MR (EuroScore II 9.0%). Of patients assigned to MVrepair, only 4.9% were treated for secondary MR (EuroScore II 3.1%).

![Decision-making algorithm of the heart team compared with estimated and experienced in-hospital mortality. MDT, multidisciplinary heart team; MR, mitral regurgitation; MV, mitral valve; MVR, surgical MV replacement.](openhrt-2020-001280f01){#F1}

###### 

Baseline characteristics of the study population (n=400)

  ---------------------------------------------------------------------------------------------------------------------
                                                  MC\                   MVrepair\         I° MVR\             P value
                                                  (n=179)               (n=185)           (n=36)              
  ----------------------------------------------- --------------------- ----------------- ------------------- ---------
  Clinical findings                                                                                           

   Age (years)                                    80.3 (8.1)            65.8 (11.6)       70.4 (11.1)         \<0.001

   Male sex, n (%)                                105 (58.7)            127 (68.6)        13 (36.1)           0.001

   EuroScore II, (%)                              6.6 (5.6)             1.7 (1.5)         3.6 (2.7)           \<0.001

   STS score mortality, (%)                       4.6 (4.0)             1.0 (1.0)         3.2 (2.1)           \<0.001

   Body mass index (kg/cm^2^)                     24.6 (4.5)            24.7 (3.4)        25.7 (4.6)          0.354

   Systolic blood pressure (mm Hg)                122.4 (22.5)          133.2 (17.5)      130.4 (22.4)        \<0.001

   Heart rate (bpm)                               77.8 (17.5)           73.2 (15.7)       75.8 (15.4)         0.040

   Atrial fibrillation, n (%)                     62 (36.9)             31 (17.1)         9 (26.5)            \<0.001

   NYHA ≥III, n (%)                               160 (92.0)            45 (27.6)         14 (45.2)           \<0.001

  Labaratory findings                                                                                         

   Haemoglobin (g/L)                              125.4 (18.9)          138.8 (13.5)      130.7 (16.2)        \<0.001

   GFR (mL/min)                                   49.9 (19.4)           77.7 (14.3)       70.6 (20.9)         \<0.001

   NTproBNP (pg/mL)                               10'998.6 (30'986.7)   677.1 (1'024.1)   2'203.8 (2'265.8)   0.014

  History of                                                                                                  

   Hypertension, n (%)                            139 (77.7)            78 (42.2)         17 (47.2)           \<0.001

   Diabetes mellitus, n (%)                       23 (12.8)             2 (1.1)           3 (8.3)             \<0.001

   Coronary artery disease, n (%)                 96 (53.6)             40 (21.6)         11 (30.6)           \<0.001

   Percutaneous coronary intervention, n (%)      68 (38.0)             15 (8.1)          2 (5.6)             \<0.001

   Coronary bypass graft surgery, n (%)           28 (15.6)             0 (0.0)           2 (5.6)             \<0.001

   Prior mitral valve intervention, n (%)         8 (4.5)               2 (1.1)           5 (13.9)            0.001

   Stroke, n (%)                                  16 (8.9)              9 (4.9)           0 (0.0)             0.074

   Chronic obstructive pulmonary disease, n (%)   25 (14.0)             4 (2.2)           1 (2.8)             \<0.001

  Mitral regurgitation                                                                                        

   ≥Moderate mitral regurgitation, n (%)          179 (100.0)           185 (100.0)       34 (94.4)           \<0.001

   Severe mitral regurgitation, n (%)             165 (92.2)            170 (91.9)        31 (86.1)           0.478

  Aetiology of mitral regurgitation                                                                           

   Primary, n (%)                                 102 (57.0)            175 (94.6)        30 (83.3)           \<0.001

   Secondary, n (%)                               64 (35.7)             9 (4.9)           4 (11.1)            \<0.001

   Combination, n (%)                             13 (7.3)              1 (0.5)           2 (5.6)             0.004

  Further echocardiographic findings                                                                          

   LVEF (%)                                       50.7 (16.4)           62.6 (7.4)        59.5 (10.3)         \<0.001

   LVEDVi (mL/m^2^)                               82.4 (39.2)           75.0 (21.4)       73.7 (23.4)         0.070

   LAVI (mL/m^2^)                                 71.4 (29.0)           64.5 (30.3)       65.9 (19.0)         0.101

   RV function reduced, n (%)                     66 (39.3)             11 (6.4)          4 (12.5)            \<0.001

   RV/RA pressure gradient                        38.9 (13.5)           29.0 (12.7)       32.6 (11.3)         \<0.001

   ≥Moderate tricuspid regurgitation, n (%)       53 (31.0)             28 (15.7)         7 (20.0)            0.003

   ≥Moderate aortic stenosis, n (%)               6 (3.6)               2 (1.1)           3 (9.1)             0.036

   ≥Moderate aortic regurgitation, n (%)          14 (8.2)              9 (5.0)           5 (15.2)            0.105
  ---------------------------------------------------------------------------------------------------------------------

GFR, glomerular filtration rate; LAVI, left atrial volume index; LVEDVi, left ventricular end diastolic volume index; LVEF, Left ventricular ejection fraction; MC, Mitraclip; MV, mitral valve; MVR, surgical MV replacement; MVrepair, surgical mitral valve repair; NTproBNP, N-terminated pro-brain natriuretic peptide; NYHA, New York Heart Association; RV, right ventricular; RV/RA, right ventricular/right atrial; STS, Society of Thoracic Surgeons.

In-hospital outcome {#s3-2}
-------------------

Treatment success rates at discharge for the initial treatment strategy MC, MVrepair and MVR were 84.9%, 89.7% and 91.7%, respectively (p=0.284). The treatment success rate for patients who underwent minimally invasive MVrepair for isolated MR was 93.6%. For MC patients, the technical success rate according to the M-VARC criteria was 99.4%.

One MC patient (0.6%) and 12 MVrepair patients (6.5%) needed peri-interventional conversion to MV replacement (secondary MVR) and were counted as failure of initial treatment strategy. Anatomical and peri-interventional factors associated with treatment success (or failure) for the three treatment arms are summarised in [table 2](#T2){ref-type="table"}. Of note, staged percutaneous interventions did not impact initial MC treatment success, while concomitant surgical procedures, in particular aortic valve replacement, were more frequent in patients in whom the surgical treatment strategy failed. A calcified leaflet and/or annulus was more frequent in patients in whom surgical MVrepair failed but had no impact on MC or MVR treatment success.

###### 

Anatomical and peri-interventional factors associated with in-hospital outcome

                                               MC (n=179)   MVrepair (n=185)   I° MVR (n=36)                                                             
  -------------------------------------------- ------------ ------------------ --------------- ------------ ----------- --------- ----------- ---------- -------
  Mitral valve anatomy                                                                                                                                   
   Calcification leaflet, n (%)                6 (3.9)      3 (11.1)           0.118           5 (3.0)      3 (15.8)    0.009     17 (51.5)   1 (33.3)   0.560
   Calcification annulus, n (%)                41 (27.0)    9 (33.3)           0.500           20 (12.0)    10 (52.6)   \<0.001   14 (42.4)   1 (33.3)   0.807
  *MV prolapse characteristics*                                                                                                                          
   Single segment, n (%)                       37 (24.3)    3 (11.1)           0.130           55 (33.1)    5 (26.3)    0.550     3 (9.1)     1 (33.3)   0.212
   Two segments ant. or post., n (%)           6 (3.9)      3 (11.1)           0.118           19 (11.4)    2 (10.5)    0.905     3 (9.1)     1 (33.3)   0.212
   Advanced only post., n (%)                  11 (7.2)     2 (7.4)            0.975           15 (9.0)     2 (10.5)    0.832     3 (9.1)     0 (0.0)    0.598
   Advanced ant.+post., not Barlow, n (%)      17 (11.2)    3 (11.1)           0.991           40 (24.1)    4 (21.1)    0.769     5 (15.2)    0 (0.0)    0.482
   Barlow, n (%)                               5 (3.3)      0 (0.0)            0.342           21 (12.7)    1 (5.3)     0.349     5 (15.2)    0 (0.0)    0.482
   Flail leaflet, n (%)                        53 (34.9)    4 (14.8)           0.039           80 (48.2)    11 (57.9)   0.426     8 (24.2)    0 (0.0)    0.348
  Extent of intervention                                                                                                                                 
   Isolated mitral valve intervention, n (%)   112 (73.7)   18 (66.7)          0.454           129 (77.7)   9 (47.4)    0.004     21 (63.6)   0 (0.0)    0.033
   MV+PCI (staged) or bypass surgery, n (%)    27 (17.8)    9 (33.3)           0.063           14 (8.4)     3 (15.8)    0.296     3 (9.1)     1 (33.3)   0.212
   MV+TAVR (staged) or SAVR, n (%)             15 (9.9)     1 (3.7)            0.304           6 (3.6)      4 (21.1)    \<0.001   3 (9.1)     2 (66.6)   0.005
   MV+TV intervention, n (%)                   1 (0.7)      0 (0.0)            0.675           21 (12.7)    4 (21.1)    0.313     7 (21.2)    1 (33.3)   0.640
   Triple valve surgery, n (%)                 --           --                 --              2 (1.2)      1 (5.3)     0.187     1 (3.0)     0 (0.0)    0.768
   Single clip intervention, n (%)             37 (24.3)    5 (18.5)           0.513           --           --          --        --          --         --
   Two clips, n (%)                            98 (64.5)    13 (48.1)          0.108           --           --          --        --          --         --
   ≥3 clips, n (%)                             17 (11.2)    9 (33.3)           0.002           --           --          --        --          --         --

ant., anterior; MC, Mitraclip; MV, mitral valve; MVR, surgical MV replacement; MVrepair, surgical mitral valve repair; NTproBNP, N-terminated pro-brain natriuretic peptide; PCI, percutaneous coronary intervention; post., posterior; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement; TV, tricuspid valve.

The median (IQR) duration of hospital stay was 5 (4--7.5) days for MC, 10 (9--12) days for MVrepair and 12 (10--19.3) days for MVR. Echocardiographic findings at discharge are summarised in [table 3](#T3){ref-type="table"}.

###### 

Echocardiographic findings at discharge

                                          MC (n=173)    MVrepair (n=182)   MVR (n=33)    P value
  --------------------------------------- ------------- ------------------ ------------- ---------
  LVEF (%)                                48.2 (16.0)   56.6 (8.4)         56.7 (7.9)    \<0.001
  LVEDVi (mL/m^2^)                        79.5 (38.4)   55.7 (16.2)        51.1 (11.4)   \<0.001
  LAVI (mL/m^2^)                          68.4 (25.1)   48.6 (28.0)        50.6 (13.4)   \<0.001
  ≥Moderate mitral regurgitation, n (%)   34 (19.7)     4 (2.2)            0 (0.0)       \<0.001
  Mean mitral gradient (mm Hg)            3.9 (1.7)     3.1 (1.2)          4.5 (1.6)     \<0.001
  RV/RA pressure gradient                 35.6 (9.4)    24.5 (6.9)         23.8 (6.3)    \<0.001
  Heart rate (bpm)                        74.7 (11.5)   80.6 (13.9)        81.5 (16.4)   \<0.001
  Haemoglobin (g/dL)                      10.8 (1.6)    10.8 (1.6)         10.1 (1.5)    0.034

Results given as mean values (±SD) except for mitral regurgitation.

LAVI, left atrial volume index; LVEDVi, left ventricular end diastolic volume index; LVEF, left ventricular ejection fraction; MC, Mitraclip; MV, mitral valve; MVR, surgical MV replacement; MVrepair, surgical mitral valve repair; RV/RA, right ventricular/right atrial.

In-hospital mortality of MC, MVrepair and MVR was 3.4%, 1.6% and 8.3%, respectively, p=0.091 ([figure 1](#F1){ref-type="fig"}).

Long-term outcome according to initial treatment strategy {#s3-3}
---------------------------------------------------------

Outcomes of the entire cohort during the mean follow-up time of 32.2±17.6 months are reported in [figure 2A, B](#F2){ref-type="fig"}. Single and multivariate regression analysis of factors predicting combined end points in MC and MVrepair patients are summarised in [table 4](#T4){ref-type="table"}.

![Long-term all-cause mortality and combined end points of the overall cohort (A and B), of Mitraclip patients according to the mitral regurgitation (MR) aetiology (C and D), and of patients with a primary MR who received an isolated repair, either by Mitraclip or surgically (E and F).](openhrt-2020-001280f02){#F2}

###### 

Predictors for combined end points

                               MC (n=179)   MVrepair (n=185)                                    
  ---------------------------- ------------ ------------------ ---------------- ------- ------- ----------------
  Univariate                                                                                    
   Age \>75 years              0.607        0.866              0.500 to 1.499   0.030   2.463   1.094 to 5.547
   Height \<170 cm             0.505        0.860              0.553 to 1.339   0.034   2.376   1.067 to 2.593
   Female                      0.166        0.723              0.457 to 1.144   0.087   2.018   0.904 to 4.508
   NYHA ≥3                     0.426        1.286              0.591 to 2.799   0.106   2.043   0.860 to 4.853
   EuroScore II \>2.5%         0.033        2.324              1.069 to 5.050   0.002   3.602   1.613 to 8.044
   Atrial fibrillation         0.900        0.970              0.607 to 1.553   0.173   1.845   0.764 to 4.453
   Anaemia                     0.047        1.565              1.006 to 2.436   0.027   2.893   1.132 to 7.396
   GRF \<60 mL/min             0.093        1.551              0.930 to 2.587   0.147   2.093   0.772 to 5.676
   LVEF \<60%                  0.002        2.315              1.377 to 3.894   0.564   0.760   0.300 to 1.930
   LVEDVi \>75 mL/m^2^         0.015        1.810              1.121 to 2.921   0.138   0.519   0.218 to 1.236
   RV function reduced         \<0.001      2.324              1.465 to 3.668   0.207   2.189   0.650 to 7.358
   RV/RA gradient \>30 mm Hg   0.929        0.975              0.562 to 1.693   0.125   2.024   0.822 to 4.981
  Multivariate                                                                                  
   EuroScore II \>2.5%         0.116        1.966              0.845 to 4.572   0.007   3.759   1.437 to 9.832
   Anaemia                     0.043        1.631              1.015 to 2.620   0.662   1.312   0.446 to 3.858
   LVEF \<60%                  0.025        2.015              1.091 to 3.723   --      --      --
   RV function reduced         0.016        1.871              1.125 to 3.109   --      --      --

GFR, glomerular filtration rate; LVEDVi, left ventricular end diastolic volume index; LVEF, Left ventricular ejection fraction; MC, Mitraclip; MVrepair, surgical mitral valve repair; NYHA, New York Heart Association; RV, right ventricular; RV/RA, right ventricular/right atrial.

When analysing the long-term impact of treatment success at discharge, failure of initial treatment strategy did not influence all-cause mortality for MC or MVrepair patients but led to more combined end points in MC patients (HR 0.528, 95% CI 0.289 to 0.964, p=0.034).

Concomitant heart treatments as well as MR aetiology were additional factors influencing outcome. Patients with combined surgical or percutaneous interventions had a significantly higher all-cause mortality compared with patients with an isolated MV intervention (surgical MV treatment: HR 3.419, 95% CI 1.300 to 8.993, p=0.008; MC patients: HR 2.753, 95% CI 1.569 to 4.832, p\<0.001). Furthermore, MC patients with secondary MR had a worse outcome compared with MC patients with a primary MR ([figure 2C, D](#F2){ref-type="fig"}). And in the subgroups of patients with primary MR with an isolated MV treatment ([figure 2E, F](#F2){ref-type="fig"}), the 4-year mortality rates were particularly low in MC patients. Women older than 75 years with small body size appear to profit from the MC procedure when analysing for combined end points at 1 year ([figure 3](#F3){ref-type="fig"}).

![Subgroup analysis to evaluate whether MVrepair or Mitraclip may be better for patients with isolated, primary MR. GFR, glomerular filtration rate; LAVI, left atrial volume index; LVEDVi, left ventricular end diastolic volume index; LVEF, left ventricular ejection fraction; MC, Mitraclip; MV, mitral valve; MVrepair, surgical mitral valve repair; RV/RA, rightventricular/right atrial.](openhrt-2020-001280f03){#F3}

The secondary follow-up end points MR grade and dyspnoea according to NYHA class over time are shown in [figure 4](#F4){ref-type="fig"}.

![Mitral regurgitation grade (MR) and dyspnoea (New York Heart Association (NYHA) I--IV) from baseline to the last follow-up examination according to the treatment performed. MC, Mitraclip.](openhrt-2020-001280f04){#F4}

Discussion {#s4}
==========

MDT decision process {#s4-1}
--------------------

The concept of an interdisciplinary MDT is a centrepiece in modern structural heart disease treatment. Yet, there is no consensus on how the MDT should decide, and evidence supporting the effectiveness of MDT decisions for patients with severe MR is lacking. In our cohort study, we describe the selection process and outcome of an all-comer population with severe MR treated by a dedicated valvular MDT. Counter to the expectations generated by valvular guidelines, the percentage of MR patients assigned to (gold standard) surgical MVrepair was only 46.2%, while 44.8% received percutaneous repair by MC and 9.0% of patients were eligible for primary MVR. In the only other published cohort of patients with MV disease treated according to the MDT decision, the distribution was similar (23% percutaneous and 62% surgical MV repair, 15% MVR).[@R16] In our cohort, mainly patients with primary MR, favourable repair anatomy and low surgical risk were offered surgical MVrepair, while patients with elevated risk or secondary MR were treated percutaneously. Such a consequent selection process was achieved as our MDT has reduced factors often biassing treatment assignment such as patient referral to a specific doctor or financial interest of the individual MDT members.

As additional treatment options such as percutaneous MV replacement will be available in the future, selecting the right patient for the right treatment will be even more challenging.[@R17] Percutaneous MVR by compassionate use of TAVR prostheses as valve-in-valve or valve-in-ring showed lower than expected peri-interventional mortality and acceptable mid-term survival in highly selected patients.[@R9] Whether the prostheses specifically designed for transcatheter MVR will improve outcome in patients at high risk for treatment failure (ie, calcified leaflets or annulus, high surgical risk) remains to be seen.[@R20]

Effectiveness of the MDT treatment decision and room for improvement {#s4-2}
--------------------------------------------------------------------

The most important question is whether the MDT decision was the right one for the given patient. According to our data, patients assigned to MC achieved a lower in-hospital mortality than expected with surgical treatment, while patients assigned to surgical repair experienced in-hospital mortality rates that met the expectations according to EuroScore II. This was particularly relevant for patients with secondary MR treated by MC, where the reduction of the expected to the achieved in-hospital mortality was largest. Our consequent selection process thus improved the short-term outcome of high-risk surgical patients by assigning them to the lower risk percutaneous treatment option. Furthermore, the benefit of the less invasive percutaneous treatment seemed particularly relevant for MC patients who had isolated, primary MR. Long-term survival rates of these patients was excellent and better than in most previously published series.[@R21] In addition, this study corroborates previous data showing a negative impact of concomitant heart treatments on long-term survival and thus emphasises the importance of a careful selection process by the MDT.[@R23]

The best treatment option for short elderly patients remains controversial. This study suggests that 1 year outcome for women with an age \>75 years and small height (as well as patients with a calcified annulus) might have been further improved if a percutaneous approach had been chosen. Reduced MVrepair rates in women have previously been reported[@R24] and are possibly due to the lack of repair space in shorter elderly women with smaller annular dimensions and limited MV prolapse tissue. Two recent propensity-weighted analyses between surgical and percutaneous MV repair in elderly patients came to opposing conclusions, one favouring surgery and one favouring the percutaneous approach.[@R25] The reasons for these discrepant results are unclear and need further analysis by randomised controlled trials.

Limitation {#s4-3}
----------

This study has the limitations attributed to its retrospective design and data collection. In addition, the decision-making process was not defined 'a priori' but represents the common understanding of our MDT. We cannot exclude that additional factors may have influenced decisions and outcome.

The small number of patients assigned to MVR did prevent further statistical analyses. It may also account for the higher than expected in-hospital mortality in this group (one expected, three actual deaths), a mortality rate comparable to the 5.4% operative mortality in a large series of patients undergoing MVR.[@R27] It does, however, underscore the need for lower-risk percutaneous MV replacement options for this high-risk surgical group.

A similar limitation has to be acknowledged regarding patients with secondary MR. Our team opted for surgical treatment in only 13 patients (9 MVrepair, 4 MVR), as opposed to 64 patients with secondary MR treated by MC. Therefore, this study cannot answer the question which treatment option is best for functional MR.

As we are a tertiary referral centre, patients not eligible for surgical or percutaneous treatment options are sent back to the primary cardiologist for optimal medical care. These (overall few) patients were not included in our study and we do not have follow-up data on them.

Conclusion {#s4-4}
----------

This study describes the MDT selection process in assigning patients for MR treatment and relates it to outcome. Only low-risk patients with favourable anatomy were offered MVrepair, while high-risk patients underwent MC or MVR. This strategy was associated with lower than expected in-hospital mortality for MC patients and high 4-year survival rates for MVrepair and MC patients with isolated primary MR.
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